PedAM
Pediatric Disease Annotations & Medicines
| Disease | hyperglycemia |
| Phenotype | |type 2 diabetes |
| Sentences | 186 |
| PubMedID- 26024569 | Purpose: although newer agents (dipeptidyl peptidase [dpp]-4 inhibitors and glucagon-like peptide [glp]-1 receptor agonists) are available for the treatment of hyperglycemia in patients with type 2 diabetes mellitus (t2dm), the impact of the availability of these agents on the use of second-generation sulfonylureas (sus) is unknown. |
| PubMedID- 22879786 | Hence medications that successfully control hyperglycemia in type 2 diabetes patients are of utmost importance. |
| PubMedID- 23130315 | Inhibition of dpp-4 is now a well-established therapeutic principle to lower hyperglycemia in patients with type 2 diabetes. |
| PubMedID- 20042772 | The ada and the european association for the study of diabetes (easd) published a consensus statement on the approach to management of hyperglycemia in individuals with type 2 diabetes (80) and a subsequent update (81). |
| PubMedID- 22009626 | The pathophysiology of hyperglycemia in type 2 diabetes (t2dm) involves 3 main defects: insulin deficiency, excess hepatic glucose output, and insulin resistance. |
| PubMedID- 26197936 | These inconsistencies may be due to the extent and duration of hyperglycemia as patients with type 2 diabetes may remain undiagnosed and therefore untreated for years, whereas the rats in this study were only diabetic for a period of 4 weeks. |
| PubMedID- 23418497 | Both type 1 and type 2 diabetes lead to hyperglycemia that further results in a number of complications, including damage to nerves (diabetic neuropathy) [2]. |
| PubMedID- 23185367 | Hepatic overproduction of glucose is a prominent contributor to hyperglycemia in patients with type 2 diabetes, and this overproduction may be a consequence of chronic and postprandial hyperglucagonemia [33], [34]. |
| PubMedID- PMC3554319 | Management of hyperglycemia in type 2 diabetes: a patient-centered approach. |
| PubMedID- 23882035 | Together, these defects cause hyperglycemia in patients with type 2 diabetes. |
| PubMedID- 25325279 | hyperglycemia in patients with type 2 diabetes is caused by multiple defects, including insulin resistance, impaired insulin secretion, and excessive hepatic glucose production. |
| PubMedID- 25722966 | Nevertheless our conclusions are similar and further strengthen their conclusions that vitamind3 supplementation might not decrease insulin resistance and hyperglycemia in patients with established type 2 diabetes. |
| PubMedID- 21228312 | On the other hand, acute correction of postprandial hyperglycemia in type 2 diabetes is expected to increase fatty acid oxidation at the expense of glucose oxidation (11), leading to increased muscle fatty acid use in the latter. |
| PubMedID- 22296854 | Effect of percutaneous electrical muscle stimulation on postprandial hyperglycemia in type 2 diabetes. |
| PubMedID- 26450424 | hyperglycemia in type 2 diabetes is associated with micro- and macro-complications [5] and causes autonomic nervous dysfunction. |
| PubMedID- 24741511 | [23161718] figure 1 summarizes the ada-easd recommended algorithm for the management of hyperglycemia in type 2 diabetes mellitus (t2d). |
| PubMedID- 22768584 | [medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the american diabetes association and the european association for the study of diabetes]. |
| PubMedID- 25905339 | These pathophysiologic abnormalities should be considered for the treatment of hyperglycemia in patients with type 2 diabetes. |
| PubMedID- 25284699 | Glucagon-like peptide-1 receptor (glp-1) agonists and dipeptidyl-peptidase-4 (dpp-4) inhibitors are therapies that are used to treat hyperglycemia in patients with type 2 diabetes mellitus. |
| PubMedID- 23670996 | It is hoped that targeting therapy at the metabolic perturbations underlying hyperglycemia in patients with type 2 diabetes will have a similar benefit (27). |
| PubMedID- 23761972 | Sitagliptin (januvia [merck, whitehouse station, nj, usa]) is a highly selective dipeptidyl peptidase-4 (dpp-4) inhibitor available for the treatment of hyperglycemia in patients with type 2 diabetes,40,41 and simvastatin (zocor™ [merck]) is an hmg-coa reductase inhibitor available as an adjunctive treatment to diet for reducing elevated ldl-c and other lipids in patient with primary hypercholesterolemia and is indicated for reducing the risk of cardiovascular mortality.42 an fdc tablet of sitagliptin and simvastatin (juvisync™ [merck]) has been approved and provides an option for use in patients for whom treatment with both sitagliptin and simvastatin is appropriate. |
| PubMedID- 23576884 | Background: the purpose of this paper is to review the efficacy, safety, and tolerability of linagliptin in the management of hyperglycemia in adults with type 2 diabetes mellitus. |
| PubMedID- 23171858 | Both the american diabetes association (ada) and the european association for the study of diabetes (easd) have published algorithms for management of hyperglycemia in patients with type 2 diabetes [1,2]. |
| PubMedID- 20299485 | Based on the above considerations, we have compared aspirin with the no-donating agent ncx 4016 for their effects on the platelet hyperreactivity induced by acute, short-term hyperglycemia in patients with type 2 diabetes. |
| PubMedID- 25962102 | To date, several dpp-4 antagonists have been identified that ameliorate hyperglycemia in type 2 diabetes patients [8, 9]. |
| PubMedID- 25810947 | It has also been demonstrated that acute hyperglycemia in people with type 2 diabetes significantly impaired speed of information processing, working memory, and some aspects of attention [31]. |
| PubMedID- 25271207 | Dapagliflozin, an insulin-independent sodium-glucose cotransporter 2 (sglt2) inhibitor, increases glucosuria and reduces hyperglycemia in individuals with type 2 diabetes. |
| PubMedID- 25317173 | Early macrovascular atherosclerosis may play a crucial role in subtle brain atrophy in type 2 diabetes mellitus patients, with chronic hyperglycemia playing a lesser role. |
| PubMedID- 20413513 | The 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor incb13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy. |
| PubMedID- 23209929 | It has also been suggested that chronic exposure to hyperglycemia and hyperinsulinemia, in patients with type 2 diabetes, could contribute to the proliferation of hepatic stem cells, at higher risk for malignant transformation [10]. |
| PubMedID- 24495364 | Background: type 2 diabetes along with chronic hyperglycemia may result in cognitive impairment. |
| PubMedID- 21294708 | Epidemiological studies, meta-analyses and systematic reviews have been used to create algorithms for the treatment of hyperglycemia in patients with type 2 diabetes. |
| PubMedID- 24341330 | The persistent hyperglycemia in patients with type 2 diabetes mellitus is strongly associated with microvascular and macrovascular complications [1]. |
| PubMedID- 22332001 | The hyperglycemia associated with type 2 diabetes also appears to impair gap junctional communication between astrocytes as shown in (1) cultured astrocytes harvested from 1-day-old wistar-hanover rats and exposed to high glucose, and (2) brain slices from 20-to-24-week-old stz rats [72]. |
| PubMedID- 24843713 | In japan, several cases of severe hyperglycemia in patients with type 2 diabetes after initiation of the glp‐1 receptor agonist, liraglutide, as replacement for insulin were reported15. |
| PubMedID- 21495788 | A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (sglt) inhibitors: systematic review and meta-analysis of randomized trials. |
| PubMedID- 25274989 | Excessive or inadequate glucagon secretion promoting hepatic gluconeogenesis and glycogenolysis is believed to contribute to hyperglycemia in patients with type 2 diabetes. |
| PubMedID- 20971966 | Given that a lack of suppression of glucagon secretion contributes to hyperglycemia in individuals with type 2 diabetes (47), the development of a physiologically regulated human α-cell line may have significant utility as a screening tool for the identification of novel therapeutics that suppress glucagon secretion. |
| PubMedID- 24857350 | Background: chorea is a common presenting feature of metabolic disorders, including nonketotic hyperglycemia in patients with type 2 diabetes mellitus, but rarely has been reported in diabetic ketoacidosis, hypothyroidism and vitamin b12 deficiency. |
| PubMedID- 24532508 | Our results indicated that we were able to induce hyperglycemia with type 2 diabetes and establish a chronic stress model in mice. |
| PubMedID- 22524271 | Diets based on refined carbohydrate foods that are quickly digested, absorbed, and metabolized (i.e., high glycemic index diets) have been associated with increased risk of lifestyle diseases in particular with an increased risk of type 2 diabetes, because of postprandial hyperglycemia and hyperinsulinemia related to eating high-gi carbohydrates. |
| PubMedID- 22432105 | The pattern of diabetes therapy reported here aligns with the recent consensus statement of the american diabetes association and the european association for the study of diabetes on the medical management of hyperglycemia in type 2 diabetes (13). |
| PubMedID- 21144857 | Chronic hyperglycemia in type 2 diabetes indeed associates with mild cognitive impairments [267]. |
| PubMedID- 26015297 | In addition to hyperglycemia, patients with type 2 diabetes have hyperinsulinemia as a result of insulin-resistance. |
| PubMedID- 23816355 | Exercise has been widely recognized to ameliorate insulin resistance and hyperglycemia in individuals with type 2 diabetes mellitus (t2dm) [1,2]. |
| PubMedID- 23165572 | [metoclopramide as a risk factor for postprandial hyperglycemia in type 2 diabetes]. |
| PubMedID- 23402455 | The american diabetes association and european association for the study of diabetes issued a new patient-centered approach for the management of hyperglycemia in patients with type 2 diabetes. |
| PubMedID- 25239210 | Constant hyperglycemia in individuals with type 2 diabetes can cause microvascular and macrovascular complications that lead to early morbidity and mortality. |
| PubMedID- 23220949 | Effect of additional administration of acarbose on blood glucose fluctuations and postprandial hyperglycemia in patients with type 2 diabetes mellitus under treatment with alogliptin. |
| PubMedID- 23737732 | This mouse spontaneously exhibits type 2 diabetes, associated with mild hyperglycemia, mild glucose intolerance, mild hyperinsulinemia, mild obesity, and mild microalbuminuria. |